ALK-rearranged and EGFR wild-type lung adenocarcinoma transformed to small cell lung cancer: a case report
BackgroundCases of ALK-rearranged EGFR wild-type lung adenocarcinoma (LUAD) transforming into small cell lung cancer (SCLC) are rarely reported, and diagnosis is often delayed. The emergence of this transformation phenomenon is often regarded as a consequence of acquired resistance mechanisms.Case p...
Main Authors: | Rui Chen, Yan Jian, Yuzhen Liu, Junping Xie |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2024-04-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2024.1395654/full |
Similar Items
-
Safety of Surgery after Neoadjuvant Targeted Therapies in Non-Small Cell Lung Cancer: A Narrative Review
by: Tomasz Marjanski, et al.
Published: (2021-11-01) -
Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK‐rearranged lung cancer
by: Mi Ran Yun, et al.
Published: (2019-12-01) -
Association of smoking and ALK tyrosine-kinase inhibitors on overall survival in treatment-naïve ALK-positive advanced lung adenocarcinoma
by: Zhe-Rong Zheng, et al.
Published: (2023-03-01) -
The Impact of Clinical Factors, ALK Fusion Variants, and BIM Polymorphism on Crizotinib-Treated Advanced EML4–ALK Rearranged Non-small Cell Lung Cancer
by: Yen-Ting Lin, et al.
Published: (2019-09-01) -
Ceritinib in the treatment of ALK-positive patients with nonsmall-cell lung cancer
by: K. K. Laktionov, et al.
Published: (2019-06-01)